Indole-5-Carboxylic Acidum CAS 1670-81-1 Puritas >99.0% (HPLC)

Description:

Nomen chemica: Indole-5-Carboxylic Acid

CAS: 1670-81-1

Puritas: >99.0% (HPLC)

Aspectus: Lux Yellow ad Orff pulveris

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Shanghai Ruifu Chemical Co., Ltd. est primarium fabricae et supplementi acidi Indole-5-Carboxylici (CAS: 1670-81-1) cum magna qualitate, productione commerciali.Gratum ad ordinem.

Chemical Properties:

Nomen chemicum	Indole-5-Carboxylic Acidum
Synonyma	1H-Indole-5-Carboxylic Acidum;5-Indolecarboxylic Acid
CAS Number	1670-81-1
CATTUS Number	RF-PI1578
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C9H7NO2
M. Pondus	161.16
Solubilitas	Solutum in Methanol, Ethanol
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Lux Yellow ut Orff pulveris
1 H NMR Spectrum	Congruunt cum Structure
Puritas / Analysis Methodus	>99.0% (HPLC)
Liquescens punctum	209.0~ 214.0℃
Damnum in Siccatio	<1.00%
Totalis immunditias	<1.00%
Solubilitas in Methanol	Prope diaphanum
Test Standard	Enterprise Standard
Consuetudinem	Pharmaceutical intermedia

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

Acidum Indole-5-Carboxylicum (CAS: 1670-81-1), Reactant ad praeparationem dioxygenasi inhibitores pyridyl-ethenyl-indoles, ut potentiales anticancer immunomodulatores;Reactant ad praeparationem indolyl-quinolinarum per metalla- rum et reactionem copulationis autoxidativae solvendo;Reactant ad praeparationem acida anthranilica utentes bromamine-B oxidant et palladium chloridi catalysti;Reactant synthesim derivatorum indirubin;Reactant ad praeparationem inter conjugates cum ketoprofen, ut inhibitores transcriptionis Gli1-mediatae in via Hedgehog;Reactant ad praeparationem analogorum piperazini-bisamidei sicut incrementum humani secretagogi hormonum receptoris antagonistae ad curationem adip.